论文部分内容阅读
将门诊收集符合本研究条件的早期相对低危T2DM患者38例,随机分成二组,治疗组使用二甲双胍500mg,tid+普伐他汀20mgqn,对照组单用二甲双胍500mg,tid,结果:治疗组总有效率94.73%,对照组总有效率84.21%,治疗组明显高于对照组,两组比较差异具有统计学意义(P<0.05)。两组治疗前后血尿常规、肝肾功能均无明显变化,也未发现其他药物不良反应。结论:二甲双胍+普伐他汀组降血糖优于二甲双胍组。
Thirty patients with T2DM were randomly divided into two groups: metformin 500mg, tid + pravastatin 20mgqn and metformin 500mg, tid alone in the control group. Results: The total effective rate in the treatment group 94.73% in the control group and 84.21% in the control group. The treatment group was significantly higher than that of the control group, with significant difference between the two groups (P <0.05). Before and after treatment, the two groups had no obvious changes in hematuria, liver and kidney function, and no adverse reactions of other drugs were found. Conclusion: The blood glucose of metformin + pravastatin group is better than that of metformin group.